|
|
|
|
|
| Profile |
Welichem Biotech Inc. (“Welichem” or “the Company”) is a publicly traded company (Toronto Stock Venture Exchange, TSX-V: WBI) engaged in the discovery, development, and commercialization of pharmaceutical drugs, through its unique, patented SymbioChem® technology platform. More...
|
| Highlights |
- Phase I Clinical Trials – Approved by Health Canada and currently underway
- Strong Pipeline – Discovery and development of two classes of drugs with distinctive disease targets:
- WBI-1000 series for autoimmune/inflammatory diseases, psoriasis
- WBI-2000 series for cancer
- Huge Market Potential – Targeted markets exceed $ US 70 billion annually
- Excellent National Standing – The 7th largest research and development life sciences company in Canada
- Extensive IP Protection – Ten patents worldwide with 29 additional patent applications pending
- Advantageous Position – Phase I Clinical Trials under way for the topical treatment of Psoriasis. Pre-clinical trials in progress for cancer treatment and reduction of potentially fatal side effects of chemotherapy
- Attractive Acquisition or Joint Venture Candidate – Welichem’s synergistic patented small molecule drug candidates should attract major pharmaceutical companies needing to increase their new drug pipelines by licensing or acquisition
|
|
 |
|
::: Copyright © 1995 - 2007 Welichem Biotech Inc. All Rights Resevered :::
|
|
|